Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 64.12

+4.9%

2:32 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: B O Trust who wrote (26214)	3/19/2008 5:50:35 AM
From: B O Trust	of 52153

DIAMYD® DIABETES VACCINE PHASE III APPROVED WILL START PHASE III IN BOTH EUROPE AND US Diamyd got amazingly good results from their Phase II vaccine trials. They have a vaccine that gives true hope with no side effects. Patients (their parents) shows strong interest to participate in Diamyd Phase III studies. One can understand them. It must be appropriate for responsible parents to participate only by looking at those results so far. Diamyd have demonstrated statistically significant long-term efficacy in preservation of beta cell function = insulin producing capacity in patients with type 1 diabetes. Looking forward: * This company probably have THE vaccine i.e efficient and SAFE working with NO treatment-related side effects. Unexpensive and easy to give. * Partnership discussions or sublicencing this vaccine will eventually result = increase company valuation. * All important approvals in place to start three Phase III trials * Interesting Phase I study in chronic pain (approved starting 2008), and several other diseases will follow. diamyd.se

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next